Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the…
DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology’s coverage of osteoarthritis (OA) pain comprises epidemiological estimates of key patient populations in the mature pharmaceutical markets (the United States, France, Germany,…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse disease progression, preserve lung…
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier…
The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are also…
The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe…
